Resistell AG announces completion of clinical pilot Performance Evaluation Study

We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.

Diversity Series: Manuela

Welcome to the last article of HEMEX’s diversity series! Today we want to introduce you to our newest team member Manuela. Manuela grew up in Basel, Switzerland, and is currently studying medicine at the University of Basel. Curious about what brought her to HEMEX? Let’s keep reading and find out!

Phagomed Acquired By BioNTech SE

The Austrian biotech company is developing endolysins and phages as therapeutics, focusing on persistent bacterial infections that cannot be targeted with broad-spectrum antibiotics. This acquisition is a big step for the AMR crisis and the formerly Phagomed team. At HEMEX, we wanted to congratulate them on their fantastic job!

How to create an inclusive and responsive society?

December 3rd is the international day of people with disabilities. Therefore, on this day, we’d like to raise awareness on the dignity and well-being of persons with disabilities while fostering a deeper understanding of the topic.

Diversity Series: Luana & Leonardo

Continuing with HEMEX’s diversity series, we want to introduce you to our new team members Leonardo and Luana. Leonardo grew up in Milan, Italy, and Luana in the canton of Basel-Land, Switzerland. Both are dedicated to improving our society’s health system, and we are delighted with these new fresh ideas in our team! Do you want to know what brought them to HEMEX? Keep reading to find out.